Purpose: We determined the characteristics of Chinese men undergoing initial prostate biopsy and evaluated the relationship between prostate specific antigen levels and prostate cancer/high grade prostate cancer detection in a large Chinese multicenter cohort. Materials and Methods: This retrospective study included 13,904 urology outpatients who had undergone biopsy for the indications of prostate specific antigen greater than 4.0 ng/ml or prostate specific antigen less than 4.0 ng/ml but with abnormal digital rectal examination results. The prostate specific antigen measurements were performed in accordance with the standard procedures at the respective institutions. The type of assay used was documented and recalibrated to the WHO standard. Results: The incidence of prostate cancer and high grade prostate cancer was lower in the Chinese cohort than the Western cohorts at any given prostate specific antigen level. Around 25% of patients with a prostate specific antigen of 4.0 to 10.0 ng/ml were found to have prostate cancer compared to approximately 40% in U.S. clinical practice. Moreover, the risk curves were generally flatter than those of the Western cohorts, that is risk did not increase as rapidly with higher prostate specific antigen. Conclusions: The relationship between prostate specific antigen and prostate cancer risk differs importantly between Chinese and Western populations, with an overall lower risk in the Chinese cohort. Further research should explore whether environmental or genetic differences explain these findings or whether Accepted for publication August 29, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
they result from unmeasured differences in screening or benign prostate disease. Caution is required for the implementation of prostate cancer clinical decision rules or prediction models for men in China or other Asian countries with similar genetic and environmental backgrounds.
Key Words: biopsy, China, early detection of cancer, prostatic neoplasms, prostate-specific antigen THE incidence of prostate cancer in East Asian countries is much lower than in Western countries. 1 That said, the incidence of PCa in China has been increasing rapidly, likely due to a longer life expectancy and Westernized lifestyles associated with dramatic economic growth and sociocultural changes. 2 Data from the PBCG have demonstrated the relationship between PSA and PCa and high grade PCa (defined as Gleason score 7 or higher) varied between the cohorts depending on characteristics such as biopsy technique, and whether biopsy decisions involved clinical evaluation or occurred for all men with an increased PSA. 3 The PBCG was restricted to cohorts from Europe and North America. There are differences between Asian and Western populations 4 and, thus, the relationship between PSA and PCa detection rate may differ between these populations as summarized in a recent review. 5 In this study we determined the characteristics of Chinese men undergoing initial prostate biopsy, and evaluated the relationship between PSA and the detection of PCa and HGPCa in a nationwide, multicenter biopsy cohort.
MATERIALS AND METHODS
The study was approved by the ethics committee at each participating hospital. We retrospectively collected information from consecutive patients undergoing initial transrectal ultrasound guided or transperineal prostate biopsies at 22 tertiary hospitals in 10 provinces across China between January 2010 and December 2013. All hospitals but 4 are listed among the top 100 hospitals in China, 6 ensuring high quality pathology review. Magnetic resonance imaging was not routinely used at any center for prostate cancer diagnosis.
Urology outpatients underwent biopsy for a PSA greater than 4.0 ng/ml regardless of DRE results or a PSA less than 4.0 ng/ml but with abnormal DRE results, defined as nodularity on palpation. Patients presented as urology outpatients for lower urinary tract symptoms, other urological symptoms or self-initiated health evaluations. PSA and DRE were given to all men of appropriate age. Decision to biopsy was based on clinical judgment, taking into account factors such as prostate volume, symptoms and, in some cases, free-to-total PSA ratio. Patients with suspicion of urinary tract infections, urinary retention, or instrumentation or catheterization of the urethra within 2 weeks were excluded from analysis, as were those who had received 5a-reductase inhibitors in the last 2 months. Transrectal ultrasound measured prostate volume was calculated with D1ÂD2ÂD3Â(p/6). PSA measurements were performed in accordance with the standard assays and procedures at the respective institutions with recalibration to the WHO standard (PSA-WHO 96/670) using the appropriate correction factor.
The probability of biopsy detected PCa and HGPCa at a given PSA was calculated by locally weighted scatterplot smoothing (LOWESS), 7 allowing comparability between the current findings and prior reports from this group. 3 Patients with a PSA less than 100 ng/ml were included in the calculation of the risk curve but risk curves were displayed only for PSA values of 10.0 ng/ml or less. The distribution of PSA in Chinese and Western cohorts was calculated using kernel density methods and excluded the clinical trial cohorts on the grounds that we were interested in the PSA distributions of patients presenting in clinical practice. All analyses were conducted using StataÒ 13.0.
RESULTS

Patient Characteristics
Of the 17,295 patients initially reviewed 2,104 were excluded for increased white blood cells in urine within 2 weeks of biopsy, 1,033 were excluded for taking 5a-reductase inhibitors within 2 months before the PSA test, 152 were excluded for repeat biopsies and 102 were excluded for recent urinary catheter manipulation. The final data set included 13,904 biopsies with 6,123 cancers detected. Among those included 13,203 cases were due to a PSA greater than 4.0 ng/ml regardless of DRE results and 701 cases were due to a PSA less than 4.0 ng/ml but with abnormal DRE results. The study population is representative of routine clinical care in China. The distributions of PSA in the Chinese and Western clinical cohorts are shown in figure 1. PSA at presentation is clearly much higher in the Chinese cohorts. As expected, patients with PCa were older (median 72 vs 68 years, p <0.0001), with a higher PSA (median 26.1 vs 10.4 ng/ml, p <0.0001) and smaller prostate volume (median 40.2 vs 47.5 ml, p <0.0001, table 1). HGPCa accounted for 77% of diagnosed PCa, with 38% and 39% of patients having a Gleason score of 7 or 8 or greater, respectively (supplementary table 1, http://jurology. com/). Among the patients who were diagnosed with PCa 58% had a PSA greater than 20 ng/ml and 23% had PSA 10 to 20 ng/ml, whereas only 20% had a PSA less than 10 ng/ml (table 2). Although the number of patients with a PSA less than 4 ng/ml was low in relative terms (5.1%), it constitutes a large number of patients in absolute terms (701).
PCa Detection Rates
Overall, cancer was found in 44% of biopsies. The relationship between PSA and PCa is presented in table 2 and figure 2, A, showing 2 notable features of this risk curve. 1) It is relatively flat, especially at low PSA levels. The risk of PCa did not change substantially in the PSA range of 0 to 4 ng/ml and the risk increased by only 6% in absolute terms from a PSA of 4 ng/ml to 10 ng/ml. 2) For PSAs greater than about 2 ng/ml, the risk is lower in the Chinese cohort than almost any other cohorts, and substantially lower than the 2 clinical cohorts in the PBCG. At a PSA of 4 ng/ml the risk of cancer was 21% in this Chinese cohort vs 38% and 43% in the Cleveland Clinic and Durham VA, respectively (supplementary table 2, http://jurology.com/).
HGPCa Detection Rates
Overall 29% of patients were diagnosed with HGPCa, with rates of 11% and 19% in patients with a PSA of 4.0 to 10.0 ng/ml and 10.0 to 20.0 ng/ml, respectively. The relationship between PSA and risk of HGPCa is shown in figure 2 , B. The shape of the PSA-HGPCa risk curve is quite flat up to a PSA of 8 ng/ml, with detection rates increasing only from 8% at 2 ng/ml to 12% at 8 ng/ml. In contrast, for most cohorts the risk of HGPCa increases twofold or threefold between a PSA of 2 ng/ml and 8 ng/ml (supplementary table 3, http://jurology.com/). As a result, the proportion of cancers that are high grade does not increase significantly with PSA ( fig. 3) . In comparison, for other cohorts the likelihood that a positive biopsy reflects HGPCa increases rapidly with PSA.
Detection Rate in Subgroups by Age and Biopsy Schemes
Patients 55 to 69 years old accounted for about 90% of participants in the ERSPC cohorts. 8 The cancer detection rate of this age group was lower than the entire cohort (36% vs 44%, chi-square test p <0.0001). The predicted detection rate was approximately 17% and 25% for a PSA of 4.0 and 10.0 ng/ml in this age group, respectively.
Most biopsies were performed based on systematic 8, 10 and 12-core schemes with a PCa detection rate of 41%, 40% and 41%, respectively (table 1) . No center applied sextant biopsies as the predominant scheme. However, some physicians used sextant biopsy for patients at higher risk, such as higher PSA values, suspicious ultrasound results or abnormal DREs. Thus, sextant biopsies yielded higher detection rates than those of the entire cohort (64% vs 41%, p <0.0001). Saturation biopsies detected more PCa cases at PSA 4.0 to 10.0 ng/ml but HGPCa detection rates were similar to the 8, 10 and 12-core schemes.
Relationship between Prostate Volume and PCa Risk
As an exploratory analysis we used logistic regression to determine whether the relationship between prostate volume and PCa risk varied between the Chinese cohorts and PBCG cohorts after adjusting for age. Although we saw statistically significant differences between the Western and Chinese cohorts (p¼0.034), these differences were not clinically meaningful. For instance, the risk of high grade disease decreased from 10% to 7.5% in Western cohorts as volume increased from 40 to 60 ml. The equivalent risks for the Chinese cohorts were 25% to 20%, that is, a relative risk of 0.8 vs 0.75.
DISCUSSION
Our results indicated that Chinese men tend to undergo biopsy at a later stage, with higher PSA and Gleason scores. The current cohort was unique compared with the PBCG cohorts in terms of the risk of PCa and the shape of the risk curve. 3 The detection rates of PCa and HGPCa were lower in the Chinese cohort than the Western cohorts at any given PSA. Moreover, the risk curves were generally flatter than those of the Western cohorts, that is risk did not increase as rapidly with higher PSA.
Possible explanations for these findings fall into 1 of 2 classes. It may be an artifact of the study population and clinical decision making, such as age, number of biopsy cores, pathology or perhaps most obviously, selection criteria for biopsy. The other explanation is biological differences between the Chinese and the Western populations, due to either environmental or genetic factors.
With respect to the selection criteria for biopsy, risk is increased if urologists use clinical criteria in addition to PSA to determine a biopsy indication. However, the risk in the Chinese cohort at a given PSA is less than the risk in the ProtecT, G€ oteborg and Rotterdam cohorts, all of which involved biopsy for increased PSA regardless of other risk factors. Therefore, any differences in biopsy selection would tend to increase risk at a given PSA in the Chinese cohorts, the opposite of the effect seen. Moreover, the PCa detection rate in a largest screening study in China was 11% for patients with PSA 4 to 10 ng/ml, even lower than what we report here. 9 Thus, selection criteria for biopsy are unlikely to explain the observed differences.
The age of patients in the Chinese cohort (median 70; quartiles 73, 76) was higher than that of all Western cohorts (median 61 to 67 years). 3 As the incidence of PCa, and HGPCa in particular, increases with age, we would expect that the detection rate in the Chinese cohort would be even lower if standardized for age. In an analysis restricted to the age group of the ERSPC participants, we again found a lower risk in the Chinese cohort. Therefore, age is also not a plausible explanation. Prostate volume was higher in the Chinese cohorts. This could theoretically lead to a higher rate of missing PCa at biopsy and, thus, lower the PCa detection rate in the Chinese cohort. However, this would not explain differences in the shape of the risk curve.
Prior exposure to PSA testing tends to decrease overall risk and to flatten the risk curve. However, again the results are in the opposite direction of those expected, with more prior screening in Western cohorts but a lower risk and a flatter risk curve in the Chinese cohorts.
In addition, there may be differences in pathological grading between the Chinese and PBCG cohorts. Indeed, this would be expected given that the Chinese cohort is more recent and that grading practices have changed with time, specifically that many of what used to be described as Gleason 6 tumors would now be described as Gleason 7, 10 as the 2005 modified Gleason pattern 4 includes most cribriform patterns and poorly formed glands. 11 However, while this might explain differences in the absolute risk of HGPCa reported here, it would not explain differences in the shape of the risk curve. It seems highly unlikely that there has been a gross underreporting of PCa by Chinese pathologists.
There were differences in screening across these included cohorts (supplementary table 1, http:// jurology.com/). PSA screening is only rarely performed in China and there is poor acceptance of screening. Only 10% of patients are willing to undergo a PSA test, even in Hong Kong, where people have better access to medical resources. 12 Finally, close to 70% of the patients in the Chinese cohort had 10 or more biopsy cores, which was higher than that of ERSPC and Prostate Cancer Prevention Trial cohorts (primarily 6-core) and comparable to that of Cleveland Clinic (8-core or more) and Durham VA (6, 10 and 12-core).
As such, none of these explanations is adequate for these findings. Indeed, compared to the ERSPC, detection rates in the Chinese cohort may have been even lower if all men were biopsied for increased PSA, age was lower, the rate of prior screening similar and sextant biopsy used. Therefore, we hypothesize that genetic or environmental differences between Chinese and Western populations led to a lower risk of cancer for a given PSA as well as differences in the shape of the risk curve. An increase in PSA may be caused by malignant and benign conditions and, thus, between cohort differences in PCa risk at a given PSA may result from differences in the relative incidence of PCa compared to benign disease. As infection was an exclusion criterion, the incidence of benign prostatic hyperplasia and chronic inflammation is of key interest. It has been reported in clinic 13, 14 and at autopsy 15 cohorts that the incidence of PCa is lower, but that of benign prostatic hyperplasia similar between Asian and Western populations. A possible explanation for the reduced incidence of PCa in Asia is dietary. Traditional East Asian food, high in isoflavones 16 and use of green tea, 17 has been linked to a lower incidence of PCa. Moreover, several studies have reported that the incidence of PCa in Asian immigrants to North America 18e20 and European countries 21e23 is substantially higher than in their home countries, again suggesting a dietary explanation. Previous reports suggest that serum levels of total and bioavailable testosterone do not differ between the Chinese and Caucasians. 24, 25 As such, we do not believe that differences in testosterone explain our results.
There are several limitations to our study. Data on DRE and family history were missing. PCa has historically been extremely rare in China, 1,14 so we would expect a low incidence of positive family history. Moreover, positive DRE or family history would lead to a bias in the opposite direction to that observed. In addition, this study is based on a clinical cohort. This issue should be recognized in making comparisons with screening cohorts. There are also inherent limitations of multicenter studies, with biopsies performed by different urologists and slides reviewed by different pathologists. Yet while this effect is likely to add statistical noise, it is unlikely that it would lead to the large systematic differences observed here. 
CONCLUSIONS
The relationship between PSA and PCa risk varies importantly between Chinese and Western populations, with an overall lower risk in the Chinese cohort. Our findings raise concerns about clinical decision rules, such as biopsying men with increased PSA, or prediction models for clinical practice in China or other Asian countries with similar genetic and environmental backgrounds. Further research should explore whether the differences observed between Western and Chinese men can be explained in terms of environmental or genetic factors.
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